Despite the relatively high rate of ANA positivity, only a small proportion of patients develop DIL, i.e., the frequency of DIL was <1% in most studies, and infliximab, which is a chimeric-murine mAb, is the TNF-α inhibitor that most commonly causes DIL. Here, TNF is linked to drug-induced lupus erythematosus.